Related Experiment Video
Updated: Apr 28, 2026
08:31
Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
Published on: September 12, 2025
1.0K
Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective
Madhav Desai1, Kate Newberry1, Zhishuo Ou1
1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Therapeutic Advances in Hematology
|June 3, 2014
Summary
Lenalidomide shows promising efficacy in treating relapsed/refractory mantle cell lymphoma (MCL). Its unique mechanisms offer advantages over other agents for MCL patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Lenalidomide is an immunomodulatory drug approved for myelodysplastic syndrome and multiple myeloma.
- Preclinical data supported its investigation in mantle cell lymphoma (MCL).
Purpose of the Study:
- To review preclinical and clinical data of lenalidomide in relapsed/refractory MCL.
- To compare lenalidomide's efficacy and safety with other agents in MCL treatment.
Main Methods:
- Summary of preclinical studies on lenalidomide's mechanism of action.
- Review of Phase I and II clinical trials of lenalidomide in relapsed/refractory MCL patients.
Main Results:
- Lenalidomide demonstrated promising results as monotherapy and in combination regimens for relapsed/refractory MCL.
- Its immunomodulatory, anti-inflammatory, and anti-angiogenic properties contribute to antitumor efficacy.
Conclusions:
- Lenalidomide exhibits a favorable action profile and safety for relapsed/refractory MCL.
- Lenalidomide represents a promising therapeutic option for patients with relapsed/refractory MCL.
Related Concept Videos
02:56Treatment Resistent Cancers
1.1K
1.1K
02:56Treatment Resistant Cancers
2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
01:16Primary Lymphoid Organs
9.6K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
9.6K
01:28Graves' Disease I: Introduction
22
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence...
22
01:16Therapeutic Drug Monitoring: Overview and Classification
638
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
638
02:57Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K